AnaptysBio, Inc. (Nasdaq: ANAB) has announced the approval of its board of directors for the spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks Bio"). The spin-off is set to occur on April 20, 2026, with shareholders receiving one share of First Tracks Bio common stock for each share of AnaptysBio common stock held as of April 6, 2026. This strategic move aims to unlock the value of AnaptysBio's development pipeline focused on autoimmune diseases. First Tracks Bio is expected to launch with an initial cash balance of $180 million, which includes $80 million from a recently secured private placement. The private placement involves the sale of 5,791,478 shares of First Tracks Bio's common stock at a price of $13.81 per share, generating approximately $80 million in gross proceeds. The closing of this private placement is contingent upon the successful completion of the spin-off. AnaptysBio's CEO, Daniel Faga, will also serve as the CEO of First Tracks Bio, emphasizing the continuity of leadership and strategic vision post-spin-off. The company aims to focus on advancing its clinical-stage assets, including ANB033, a CD122 antagonist currently in a Phase 1b trial for celiac disease, and other promising candidates. This spin-off is expected to provide AnaptysBio with a clearer mandate to manage its royalty streams while allowing First Tracks Bio to concentrate on developing therapeutics that deliver long-term value for patients and shareholders. The announcement also includes a $100 million stock repurchase plan authorized by AnaptysBio's board, further indicating the company's commitment to enhancing shareholder value.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.